Endogenous and Synthetic Cannabinoids as Therapeutics in Retinal Disease

Figure 1

Effect of HU-210 on somatostatin’s release in rat retina. (a) HU-210 at the low dose of 10⁻¹⁶ M had no effect on the release of somatostatin ( pg/μg, ) compared to the control tissue (CTRL,  pg/μg, ). HU-210 at 10⁻¹⁴ M increased the release of somatostatin in the retina ( pg/μg, , compared to CTRL), whereas higher concentrations caused a statistically significant decrease in somatostatin’s release (10⁻¹² M,  pg/μg, , compared to CTRL; 10⁻¹⁰ M,  pg/μg, , compared to CTRL; 10⁻⁸ M,  pg/μg, , compared to CTRL; 10⁻⁷ M,  pg/μg, , compared to CTRL). Dunnett’s Multiple Comparison Test was used for the statistical analysis of the data. All values represent the mean ± SEM. (b) Effect of the CB1 preferred antagonist AM251 in the actions of HU-210 (10⁻⁷ M) on somatostatin’s release. AM251 (10⁻⁷ M) reversed the attenuation of somatostatin release by HU-210 (10⁻⁷ M) ( pg/μg, compared to HU-210, ). One-way ANOVA with Tukey’s post hoc analysis test was used for the statistical analysis of the data. All values represent the mean ± SEM.

(a)

(b)